Recipients of TEL-ABL–transduced bone marrow have increased survival compared with those givenBCR-ABL marrow.

Kaplan-Meier–style survival curve for recipients of bone marrow from donors treated with 5-flurouracil, with the marrow transduced with MSCVneo retrovirus expressing TEL-ABL (solid line) or p210 BCR-ABL (broken line). The number of recipients in each arm is shown in parentheses. The curve forBCR-ABL is a composite of data from previously described mice5 and additional mice given transplants concurrently with the TEL-ABL recipients. CML-like disease developed in all recipients in this arm. The square symbols indicate individualTEL-ABL recipient mice, with the disease phenotype of each designated by the shading (solid black indicates CML-like disease; and open indicates small-bowel necrosis with acute fatty liver). Mice with prominent histopathological features of both disease processes are indicated by multiply shaded symbols. The TEL-ABL curve is a composite of 3 independent transplantation experiments that yielded identical results. The difference in survival between recipients ofBCR-ABL–transduced and TEL-ABL–transduced marrow was significant (P < .0001 by Mantel-Cox test). All recipients of marrow transduced with TEL-ABL, ΔPNT, or K581R (large dashed or dotted lines) remained healthy.